Savara Inc. (SVRA) Research

Savara Inc. is a biopharmaceutical firm in the clinical development phase, specializing in therapies for uncommon respiratory conditions. Their primary investigational drug, molgramostim, is an inhaled form of granulocyte-macrophage colony-stimulating factor (GM-CSF). This compound is currently undergoing Phase III trials to address autoimmune pulmonary alveolar proteinosis. The company's main operations are situated in Austin, Texas.

Market snapshot

Symbol
SVRA
Price
$5.50
Day change
+2.23%
Market cap
$1.1B
P/E ratio
-10.76x
52-week range
1.98-7.005
Sector
Healthcare
Industry
Biotechnology
Next earnings
in 2 months
Analyst price target
$10.00

Peer companies

  • Bicara Therapeutics Inc. Common Stock (BCAX)
  • EyePoint Pharmaceuticals, Inc. (EYPT)
  • Geron Corporation (GERN)
  • GH Research PLC (GHRS)
  • Kura Oncology, Inc. (KURA)
  • Nanobiotix S.A. (NBTX)
  • ProKidney Corp. (PROK)
  • Rezolute, Inc. (RZLT)

Recent insider activity

  • Lowrance David L — M-Exempt (24850 shares) on 2026-03-18
  • Lowrance David L — M-Exempt (12500 shares) on 2026-03-18
  • Lowrance David L — F-InKind (16518 shares) on 2026-03-18
  • Lowrance David L — M-Exempt (43063 shares) on 2026-03-18
  • Lowrance David L — F-InKind (11037 shares) on 2026-03-18

Open Savara Inc. (SVRA) in Thesis for live fundamentals, charts, options context, and portfolio-aware Copilot follow-ups.